In last trading session, Gain Therapeutics Inc (NASDAQ:GANX) saw 0.47 million shares changing hands with its beta currently measuring 0.12. Company’s recent per share price level of $2.01 trading at $0.2 or 11.05% at ring of the bell on the day assigns it a market valuation of $59.41M. That closing price of GANX’s stock is at a discount of -58.71% from its 52-week high price of $3.19 and is indicating a premium of 55.72% from its 52-week low price of $0.89. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.26 million shares which gives us an average trading volume of 284.43K if we extend that period to 3-months.
For Gain Therapeutics Inc (GANX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 12 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Gain Therapeutics Inc (NASDAQ:GANX) trade information
Upright in the green during last session for gaining 11.05%, in the last five days GANX remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $2.01 price level, adding 2.43% to its value on the day. Gain Therapeutics Inc’s shares saw a change of -6.94% in year-to-date performance and have moved 3.61% in past 5-day. Gain Therapeutics Inc (NASDAQ:GANX) showed a performance of 15.52% in past 30-days. Number of shares sold short was 0.3 million shares which calculate 1.02 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 71.29% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -99.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -99.0% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -37.02% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 18.12% while estimates for its earnings growth in next 5 years are of -3.96%.
Gain Therapeutics Inc (NASDAQ:GANX)’s Major holders
Insiders are in possession of 4.44% of company’s total shares while institution are holding 8.43 percent of that, with stock having share float percentage of 8.82%. Investors also watch the number of corporate investors in a company very closely, which is 8.43% institutions for Gain Therapeutics Inc that are currently holding shares of the company. TIMELO INVESTMENT MANAGEMENT INC. is the top institutional holder at GANX for having 0.61 million shares of worth $0.77 million. And as of 2024-06-30, it was holding 3.3666 of the company’s outstanding shares.
The second largest institutional holder is DME CAPITAL MANAGEMENT, LP, which was holding about 0.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.1488 of outstanding shares, having a total worth of $0.72 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 167.56 shares of worth $0.34 million or 0.57% of the total outstanding shares. The later fund manager was in possession of 147.93 shares on Mar 31, 2025 , making its stake of worth around $0.3 million in the company or a holder of 0.50% of company’s stock.
